# Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

> **NCT03213002** · PHASE1,PHASE2 · RECRUITING · sponsor: **Northwell Health** · enrollment: 67 (estimated)

## Conditions studied

- Glioblastoma Multiforme (GBM)
- Glioblastoma
- Glioma of Brain
- Glioblastoma, Adult
- Brain Tumor
- Brain Tumor, Primary
- Brain Tumor Adult
- Cancer
- Brain Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03213002
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-06-13
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03213002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03213002, "Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03213002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*